147 related articles for article (PubMed ID: 25176261)
1. [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders].
Medvedev VE; Tereshchenko ON; Israelian AIu; Chobanu IK; Kost NV; Sokolov OIu; Miasoedov NF
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(7):17-22. PubMed ID: 25176261
[TBL] [Abstract][Full Text] [Related]
2. [Optimization of the treatment of anxiety disorders with selank].
Medvedev VE; Tereshchenko ON; Kost NV; Ter-Israelyan AY; Gushanskaya EV; Chobanu IK; Sokolov OY; Myasoedov NF
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(6):33-40. PubMed ID: 26356395
[TBL] [Abstract][Full Text] [Related]
3. [Subjective evaluation of the effect of single test doses of phenazepam and placebo in patients with anxiety disorders: a relationship with objective pharmaco-electroencephalography characteristics].
Neznamov GG; Bochkarev VK
Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(9):53-60. PubMed ID: 30335073
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic effect and pharmacokinetics of transdermal phenazepam preparation in patients with different anxiety disorders].
Dorofeeva OA; Siuniakov SA; Zherdev VP; Kolyvanov GB; Litvin AA; Neznamov GG
Eksp Klin Farmakol; 2009; 72(2):6-10. PubMed ID: 19441719
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].
Zozulia AA; Neznamov GG; Siuniakov TS; Kost NV; Gabaeva MV; Sokolov OIu; Serebriakova EV; Siranchieva OA; Andriushenko AV; Telesheva ES; Siuniakov SA; Smulevich AB; Miasoedov NF; Seredenin SB
Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):38-48. PubMed ID: 18454096
[TBL] [Abstract][Full Text] [Related]
6. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.
Zozulya AA; Kost NV; Yu Sokolov O; Gabaeva MV; Grivennikov IA; Andreeva LN; Zolotarev YA; Ivanov SV; Andryushchenko AV; Myasoedov NF; Smulevich AB
Bull Exp Biol Med; 2001 Apr; 131(4):315-7. PubMed ID: 11550013
[TBL] [Abstract][Full Text] [Related]
7. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.
Vyunova TV; Andreeva L; Shevchenko K; Myasoedov N
Protein Pept Lett; 2018; 25(10):914-923. PubMed ID: 30255741
[TBL] [Abstract][Full Text] [Related]
8. [Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice].
Sarkisova KIu; Kozlovskiĭ II; Kozlovskaia MM
Zh Vyssh Nerv Deiat Im I P Pavlova; 2008; 58(2):226-37. PubMed ID: 18661785
[TBL] [Abstract][Full Text] [Related]
9. Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder.
Zastrozhin MS; Antonenko AP; Nesterenko EV; Seyfullaeva LI; Mustafina VR; Esakova AP; Grishina EA; Sorokin AS; Skryabin VY; Savchenko LM; Bryun EA; Sychev DA
Drug Metab Pers Ther; 2018 Dec; 33(4):187-194. PubMed ID: 30325732
[TBL] [Abstract][Full Text] [Related]
10. Anxiolytic efficacy of alprazolam compared to diazepam and placebo.
Maletzky BM
J Int Med Res; 1980; 8(2):139-43. PubMed ID: 6102940
[TBL] [Abstract][Full Text] [Related]
11. Controlled study on the anxiolytic activity of a newly-developed benzodiazepine, metaclazepam.
Marano P; Patti F; Nicoletti F
Curr Med Res Opin; 1988; 11(1):41-4. PubMed ID: 2898320
[TBL] [Abstract][Full Text] [Related]
12. Effects of
Zastrozhin MS; Skryabin VY; Torrado M; Petrovna A; Sorokin AS; Grishina EA; Ryzhikova KA; Bedina IA; Buzik OZ; Chumakov EM; Savchenko LM; Brun EA; Sychev DA
Pharmacogenomics; 2020 Jan; 21(2):111-123. PubMed ID: 31957548
[No Abstract] [Full Text] [Related]
13. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats.
Kasian A; Kolomin T; Andreeva L; Bondarenko E; Myasoedov N; Slominsky P; Shadrina M
Behav Neurol; 2017; 2017():5091027. PubMed ID: 28280289
[TBL] [Abstract][Full Text] [Related]
14. Benzodiazepines revisited.
Balon R
Psychother Psychosom; 2013; 82(6):353-4. PubMed ID: 24061158
[No Abstract] [Full Text] [Related]
15. Benzodiazepines in clinical practice: consideration of their long-term use and alternative agents.
Stevens JC; Pollack MH
J Clin Psychiatry; 2005; 66 Suppl 2():21-7. PubMed ID: 15762816
[TBL] [Abstract][Full Text] [Related]
16. Double-blind randomized trial of the benzodiazepine derivative metaclazepam as compared with placebo treatment of outpatients with anxiety syndromes.
Laakmann G; Blaschke D; Hippius H; Schewe S
Pharmacopsychiatry; 1988 May; 21(3):136-43. PubMed ID: 2900514
[TBL] [Abstract][Full Text] [Related]
17. [Double-blind study of clobazam (Odipam) and diazepam in non-psychotic anxiety states].
Ostrogonac S; Vuckovic S
Med Pregl; 1989; 42(1-2):19-21. PubMed ID: 2569665
[TBL] [Abstract][Full Text] [Related]
18. [Study in pediatrics of an anxiolytic drug: clobazam].
Guran P
Ann Pediatr (Paris); 1976 Jun; 23(6-7):489-91. PubMed ID: 16104205
[No Abstract] [Full Text] [Related]
19. [Effect of phenazepam in various medicinal forms on psychophysical state of patients with anxiety disorders].
Neznamov GG; Dorofeeva OA; Teleshova ES; Siuniakov SA; Mametova LÉ
Eksp Klin Farmakol; 2011; 74(5):6-12. PubMed ID: 21809691
[TBL] [Abstract][Full Text] [Related]
20. Alprazolam (Xanax).
Med Lett Drugs Ther; 1982 Apr; 24(607):41-2. PubMed ID: 6123071
[No Abstract] [Full Text] [Related]
[Next] [New Search]
